Studies showed that mono therapy of metformin had 85% fewer deaths and hospitalizations then sulfonylurea.
Read More »Enhancing the Effects of Sulfonylureas when Administered with an ACE Inhibitor
ACE inhibitors may cause a temporary increase of the insulin sensitivity, which leads to an increased risk of hypoglycemia.
Read More »Sulfonylureas Only Transiently Improve Glycemic Control
Although the addition of sulfonylureas to metformin therapy improves glycemic control in type 2 diabetics, deterioration may resume in as little 6 months’
Read More »Glycemic Control Deteriorates After Sulfonylureas Added to Metformin
After 6 months deterioration of glycemic control resumes following the addition of SUs to MF.
Read More »Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added
Glycemic control is improved following the addition of SUs to MF, but deterioration resumes as early as 6 months.
Read More »The Kinetics-Effect That Causes Sulfonylureas/Glinides To Cause Hyperglycemia
Continuous sulfonylurea exposure over a certain level impairs rather than improves insulin and glucose responses to sulfonylurea.
Read More »Pioglitazone Superior to Sulfonylurea for Glycemic Control in Combo With Metform
A greater then a 1% drop in A1c was resulted from using piogliazone with metformin then glyburide with metformin.
Read More »Rosiglitazone/Sulfonylurea Has Significant Advantages over Max
Early addition of the insulin sensitizer rosiglitazone (Avandia) in older type 2 diabetic patients previously on submaximal doses of a sulfonylurea reduces disease progression and provides superior glycemic control that is sustained over two years.
Read More »Sulfonylurea’s Potentially Harmful to the Heart
A study suggests that sulfonylurea oral diabetes medications may be linked to increased risk of coronary artery spasms.
Read More »